SCHEMBL6627140

SCHEMBL6627140

[O]C(=O)Nc1cccc2c1CCCC2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
LMNA P02545 3/20 0.63
THRA P10827 1/20 0.63
THRB P10828 1/20 0.63
L3MBTL1 Q9Y468 3/20 0.61
KDM4E B2RXH2 2/20 0.61
TSHR P16473 2/20 0.60
POLB P06746 1/20 0.57
SIGMAR1 Q99720 2/20 0.55
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55
GRIN2B Q13224 1/20 0.55
GRIN2C Q14957 1/20 0.55
GRIN3A Q8TCU5 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.52
RXRA P19793 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627142 0.86 ALDH1A1 (0.65) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL2357753 0.84 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL1638724 0.84 ALDH1A1 (0.72) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL5418295 0.84 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL20456551 0.83 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL4877265 0.83 ALDH1A1 (0.70) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL19305874 0.82 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL1613763 0.81 ALDH1A1 (0.68) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL30567324 0.81 ALDH1A1 (0.68) ALDH1A1MEN1KMT2ALMNATHRA
SCHEMBL6054998 0.80 L3MBTL1 (0.76) ALDH1A1MEN1KMT2ALMNATHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US claimed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP claimed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO claimed
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE ALDH1A1 4046/4885MEN1 4485/4885KMT2A 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.